US based pharmaceutical company Abbott Labs has revealed that its everolimus-eluting coronary stent has been approved by the Food and Drug Administration for the treatment of coronary artery disease.
Abbott said that the stent, known as Xience Prime, is similar to its predecessor Xience V as it uses the same drug and biocompatible polymer but the company added that Xience Prime offers thinner struts which help it to maintain radial strength and thus offer better delivery.
AdvertisementConfirming the approval of the stent, the FDA said that its decision was based on the SPIRIT PRIME trial which tested the effectiveness of the stent in 500 patients with coronary artery disease.
The FDA revealed that the stent showed lower rates of target lesion failure and stent thrombosis at the end of one year.
You May Also Like